Strides Pharma Joins Hands with Kenox to Strengthen US Nasal Spray Portfolio

On September 8, Strides Pharma Science Ltd said that its Singapore-based arm, Strides Pharma Global Pte. Limited has entered a strategic product development deal with Kenox Pharmaceuticals Inc.

Focus on Nasal Sprays

The partnership aims to expand Strides’ nasal spray product pipeline for the US market across multiple therapeutic areas. Nasal sprays have already been highlighted as an important focus area for Strides.

Role of Kenox

Kenox, a fast-growing contract development and manufacturing organisation (CDMO) specialising in orally inhaled and nasal drug products (OINDPs), will provide its expertise in formulation and development. This will support Strides in creating and filing regulatory approvals for multiple nasal spray products.

Benefits of the Collaboration

The alliance is expected to speed up the launch of affordable, high-quality medicines in the US. Strides brings strong manufacturing and market reach, while Kenox adds deep technical know-how.

Leadership Views

• Aditya Kumar, Executive Director at Strides, said this collaboration strengthens their nasal spray strategy and accelerates growth in the US.
• Dr. Sitaram Velaga, Founder & CEO of Kenox, called the partnership a major milestone that validates their expertise in OINDPs and helps deliver affordable therapies globally.

Strides Pharma Share Price Movement

Strides Pharma Science share price (NSE: STAR) was trading at ₹881.90 on September 9 at 10:04 am IST, up 0.50 points (0.057%). The stock opened at ₹891.45, touched a high of ₹894.00, and a low of ₹881.85 during the session. The company has a market capitalisation of ₹8,140 crore, with a P/E ratio of 22.38 and a dividend yield of 0.45%. Over the past year, the stock has moved between a 52-week high of ₹972.00 and a 52-week low of ₹513.05. Strides also pays a quarterly dividend of ₹0.99 per share.

Read More: Best Gold ETFs in September 2025 Based on Expense Ratio!

Conclusion

This partnership positions Strides to tap deeper into the US nasal spray market, combining Kenox’s technical strengths with Strides’ manufacturing and distribution edge. It reflects Strides’ focus on innovation and its ambition to grow in the regulated US pharma market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in Mutual Funds are subject to market risks. Read all related documents carefully before investing.